Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA

Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA

Get latest articles and stories on Business at LatestLY. Nashik (Maharashtra) [India], May 15: Datar Cancer Genetics (DCG), a global precision oncology company, today announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has been cleared by the US Food and Drug Administration (US FDA). Business News | Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehen…